STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Tyra Biosciences, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Janus Henderson Group plc reported beneficial ownership of 2,856,290 shares of Tyra Biosciences common stock, equal to 5.4% of the class, in a Schedule 13G/A filing. The statement shows 0 shares of sole voting or dispositive power and 2,856,290 shares of shared voting and shared dispositive power, indicating the reported interest is held collectively by related entities. The filing identifies the reporting person type as IA, HC and lists indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers furnishing advice to Managed Portfolios. A power of attorney authorizes named employees to prepare and file U.S. reporting forms on the group's behalf.

Positive
  • Janus Henderson disclosed beneficial ownership of 2,856,290 shares, representing a reported 5.4% interest in TYRA common stock.
  • Filing specifies shared voting and shared dispositive power of 2,856,290 shares with 0 shares of sole power, providing clear allocation of authority.
  • The report identifies the reporting person type as IA, HC and names indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers, improving transparency.
  • A documented power of attorney authorizes named employees to execute and amend U.S. reporting forms on behalf of Janus Henderson, clarifying filing authority.
Negative
  • None.

Insights

Janus Henderson reports a material 5.4% holding in TYRA via shared voting and dispositive power.

The filing discloses 2,856,290 shares and explicitly allocates shared voting and shared dispositive power to the reporting group while showing no sole voting or dispositive power. Crossing the 5% threshold triggers public reporting and signals a visible institutional position. The classification as IA, HC and the identification of investment-adviser subsidiaries clarify the channels through which the position is managed. On its face, the disclosure is a routine institutional ownership report rather than an indication of control actions.

The Schedule 13G/A and attached power of attorney reflect centralized, compliant reporting by Janus Henderson subsidiaries.

The document names JHIUS, JHIUKL and JHIAIFML as indirect subsidiaries and includes a power of attorney granting authority to specific employees to file and amend U.S. disclosure forms. That structure supports coordinated compliance across entities and clarifies who may execute reporting obligations. The statement of shared voting and dispositive power is explicit and limits ambiguity about how the position is reported within the group.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP PLC
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Exhibit Information

POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

FAQ

Who filed the Schedule 13G/A for TYRA?

The filing was made by Janus Henderson Group plc as the reporting person.

How many Tyra Biosciences (TYRA) shares does Janus Henderson report owning?

The filing reports beneficial ownership of 2,856,290 shares of TYRA common stock.

What percentage of TYRA does the reported holding represent?

The disclosed position represents 5.4% of the class of common stock.

What voting and dispositive powers are reported by Janus Henderson?

The filing shows 0 shares of sole voting or dispositive power and 2,856,290 shares of shared voting and shared dispositive power.

Which subsidiaries are identified as involved in managing the position?

The filing names JHIUS, JHIUKL and JHIAIFML as indirect subsidiaries that are registered investment advisers furnishing advice to Managed Portfolios.

Who signed the Schedule 13G/A on behalf of Janus Henderson?

The document is signed by Kristin Mariani, Head of North America Compliance, CCO, for Janus Henderson Group plc.
Tyra Biosciences, Inc.

NASDAQ:TYRA

TYRA Rankings

TYRA Latest News

TYRA Latest SEC Filings

TYRA Stock Data

832.07M
50.67M
3.68%
108.51%
11.11%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD